rhinosinus
larg
heterogen
group
diseas
despit
fact
mani
paper
publish
topic
past
decad
littl
known
etiolog
pathophysiolog
nevertheless
amount
knowledg
avail
worldwid
literatur
chang
understand
entiti
rhinosinus
commonli
classifi
acut
ar
chronic
rhinosinus
cr
base
symptom
durat
ar
inflammatori
reaction
character
uncompl
mild
moder
case
therefor
longer
argument
prescrib
antibiot
first
line
treatment
rather
privileg
antiinflammatori
treatment
intranas
steroid
sever
complic
case
antibiot
combin
topic
steroid
remain
treatment
choic
hand
cr
actual
subdivid
two
distinct
entiti
cr
without
polyp
grow
evid
indic
entiti
specif
inflammatori
pathway
cytokin
profil
paper
review
recent
data
rhinosinus
author
hope
review
help
clinician
gain
better
understand
manag
condit
rhinosinus
heterogen
group
diseas
signific
increas
health
problem
affect
popul
western
countri
substanti
impact
patient
healthrel
qualiti
life
daili
function
repres
huge
financi
burden
societi
health
care
system
result
direct
indirect
cost
establish
rhinosinus
one
expens
disord
experienc
exampl
us
popul
basi
intern
consensu
rhinosinus
rhinosinus
subdivid
acut
subacut
recurr
chronic
rhinosinus
tabl
summar
differ
form
rhinosinus
ar
common
upper
respiratori
tract
disord
involv
inflamm
nasal
paranas
sinu
mucosa
mild
moder
sever
unlik
common
cold
typic
resolv
less
day
symptomatolog
ar
worsen
day
persist
day
case
resolv
less
week
european
posit
paper
rhinosinus
nasal
polyp
document
symptom
persist
week
intermitt
persist
primari
care
physician
diagnos
treat
larg
proport
infect
appropri
therapi
sign
symptom
ar
resolv
complet
diagnosi
ar
base
patient
histori
clinic
examin
symptomatolog
includ
nasal
congest
purul
discharg
fever
headach
facial
painpressur
dental
pain
postnas
drip
cough
tender
around
sinu
area
tabl
summar
symptomatolog
classifi
major
minor
symptom
found
case
complic
symptom
typic
worsen
recumb
posit
may
interfer
sleep
nasal
endoscopi
reveal
mucosa
turbin
red
swollen
clear
secret
turn
thicker
color
opaqu
within
day
becom
clear
symptom
resolut
symptom
requir
immedi
referr
specialist
follow
periorbit
edema
displac
eyebal
diplopia
ophthalmoplegia
impair
extraocular
movement
reduc
visual
acuiti
sever
headach
unilater
facial
orbit
pain
frontal
lump
neurolog
sign
deficit
ar
typic
preceed
viral
infect
allerg
reaction
virus
account
least
caus
agent
ar
among
rhinoviru
coronaviru
influenza
respiratori
synciti
viru
parainfluenza
viru
play
major
role
ar
becom
bacteri
infect
case
case
rs
sever
complic
particular
condit
infern
trio
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarhali
infect
must
consid
anaerob
report
case
pathophysiolog
ar
involv
interact
predispos
condit
allerg
rhiniti
septal
deform
immun
defici
environment
factor
viral
infect
consequ
inflammatori
respons
mucos
line
nose
paranas
sinus
tabl
summar
differ
predispos
factor
play
role
develop
ar
inflammatori
process
lead
develop
edema
engorg
fluid
extravas
mucu
product
obstruct
sinu
ostium
ostial
obstruct
imped
normal
ventil
drainag
sinu
decreas
partial
pressur
oxygen
decreas
ciliari
clearanc
stasi
secret
secundari
bacteri
infect
thu
ar
first
regard
infecti
process
initi
viral
infect
consid
cytokin
profil
ar
result
thelper
type
cytokin
polar
associ
high
level
tumor
necrosi
also
releas
proinflammatori
cytokin
interleukin
il
cytokin
consid
potent
chemoattract
agent
neutrophil
figur
schemat
inflammatori
cascad
case
rhinoviru
infect
goal
treatment
ar
allevi
minim
symptom
erad
pathogen
underli
caus
therapi
halt
inflamm
promot
sinu
drainag
interest
point
ar
case
resolv
spontan
within
week
tabl
summar
differ
treatment
option
case
ar
earli
phase
ar
symptomat
treatment
suffici
consist
nasal
douch
decongest
exspector
mucolyt
painkil
moder
ar
monotherapi
intranas
glucosteroid
recommend
glucocorticoid
act
glucocorticoid
receptor
inhibit
transcript
proinflammatori
mediat
upregul
inflammatori
respons
consequ
reduc
mucos
inflamm
edema
cellular
infiltr
nasal
congest
improv
permeabl
sinu
ostium
thu
facilit
ventil
drainag
sinu
reduc
eosinophilia
also
great
help
case
comorbid
allerg
rhiniti
occur
frequent
young
patient
possibl
predispos
factor
develop
ar
treatment
intranas
steroid
in
proven
safe
welltoler
incid
advers
event
greater
observ
placebo
moder
sever
case
topic
steroid
must
use
associ
broad
spectrum
antibiot
mani
studi
includ
random
placebocontrol
trial
demonstr
clinic
effect
combin
actual
provid
greater
symptomat
improv
antibiot
therapi
alon
shorter
time
recoveri
greater
regress
imag
abnorm
antibiot
chosen
acccord
local
bacteri
resist
pattern
effect
safeti
must
effect
pneumonia
h
influenza
common
bacteria
implic
uncompl
communityacquir
acut
bacteri
rhinosinus
unit
state
first
choic
amoxycillin
also
clear
use
antibiot
warrant
patient
sever
rapidli
worsen
symptom
regardless
durat
ill
referr
ear
nose
throat
specialist
mandatori
case
nasal
polyposi
subgroup
cr
remain
one
difficult
challeng
otolaryngolog
etiolog
pathophysiolog
still
unclear
medic
treatment
unsatisfactori
frequent
recurr
repeat
surgic
procedur
often
necessari
nasal
polyp
present
edemat
semitransluc
mass
origin
mucos
line
sinus
prolaps
nasal
caviti
nasal
endoscopi
show
bilater
later
middl
turbin
middl
meatu
frequent
present
superior
meatu
polyposi
unilater
anoth
diagnosi
must
consid
eg
schneiderian
papilloma
tumor
adult
dermoid
cyst
meningoencephalocel
nasal
glioma
children
symptomatolog
similar
cr
without
polyp
tabl
frequent
nasal
congest
anterior
posterior
nasal
discharg
recurr
episod
respiratori
tract
infect
reduct
loss
sens
smell
import
symptom
patient
nasal
polyp
headach
facial
painpressur
less
common
cr
without
polyp
concern
bacteriolog
organ
describ
section
chronic
rhinosinus
without
polyp
infect
nasal
polyposi
infern
trio
associ
recurr
polyposi
acut
bacteri
exacerb
sinus
antibioticresist
organ
biofilm
osteiti
also
associ
polyposi
specif
item
discuss
case
nasal
polyposi
role
bacteri
colon
enterotoxin
enterotoxin
aureu
act
local
superantigen
lymphocyt
induc
multiclon
bcell
activ
releas
cytokin
cell
result
eosinophil
activ
releas
eosinophil
cation
protein
ecp
ecp
caus
tissu
damag
edema
format
albumin
accumul
bcell
activ
result
product
multiclon
ige
plasma
contrast
patient
cr
without
polyp
evid
increas
preval
enterotoxinspecif
ige
antibodi
figur
show
possibl
role
enterotoxin
produc
aureu
pathophysiolog
nasal
polyp
nasal
polyposi
constitut
heterogen
group
diseas
base
type
inflammatori
infiltr
subdivid
nasal
polyp
two
group
eosinophil
neutrophil
tabl
list
differ
subpopul
nasal
polyp
nasal
polyposi
affect
gener
popul
western
countri
common
atop
individu
healthi
control
interest
note
belgian
popul
sensit
least
one
aeroallergen
nasal
polyposi
associ
nonallerg
asthma
nasal
polyposi
associ
aspirin
sensit
samter
triad
aspirinexacerb
respiratori
diseas
repres
subset
patient
sever
recalcitr
nasal
polyposi
asthma
set
aspirin
sensit
underli
pathophysiolog
appear
dysregul
eicosanoid
metabol
pathway
lead
increas
product
cysteinyl
leukotrien
decreas
level
prostaglandin
churgstrauss
syndrom
allerg
granulomat
angiiti
character
inflamm
small
arteri
vein
individu
histori
asthma
allergi
besid
inflamm
blood
vessel
also
increas
number
eosinophil
inflammatori
nodular
lesion
nasal
polyp
present
patient
af
associ
nasal
polyposi
case
histolog
polyp
cover
respiratori
pseudostratifi
columnar
epithelium
area
squamou
metaplasia
frequent
epitheli
damag
epithelium
shed
variabl
stage
thicken
basement
membran
pseudocyst
format
edema
two
major
characterist
nasal
polyp
pseudocyst
contain
albumin
plasma
protein
number
vessel
gland
reduc
virtual
neuron
structur
fibroblast
infiltr
inflammatori
cell
local
around
pseudocyst
format
activ
eosinophil
usual
locat
around
vessel
gland
predomin
patient
nasal
polyp
number
degranul
epitheli
mast
cell
high
nasal
polyp
ecm
sever
damag
explain
fact
balanc
mmp
tissu
inhibitor
mmp
shown
displac
favour
mmp
especi
also
demonstr
modif
angiogenesi
nasal
polyp
via
vascular
endotheli
growth
factor
vascular
endotheli
growth
factor
play
role
induc
edema
angiogenesi
fibrosi
demonstr
intens
express
nasal
polyp
mainli
inflammatori
cell
also
epitheli
cell
upregul
secret
nasal
polyposi
caucasian
patient
predominantli
eosinophil
inflamm
tabl
associ
high
level
rant
regul
activ
normal
tcell
express
secret
granulocytemacrophag
colonystimul
factor
eotaxin
play
role
recruit
activ
eosinophil
decreas
apoptosi
concentr
ecp
high
upregul
cysteinylleukotrien
synthesi
signific
differ
polyp
found
patient
without
samter
triad
asthma
explain
benefit
observ
treatment
antileukotrien
modifi
nasal
polyposi
decreas
express
accompani
upregul
tbet
gatabind
protein
downregul
treatment
in
express
increas
elev
level
total
specif
ige
polyp
tissu
anoth
major
characterist
nasal
polyposi
concentr
may
high
kul
often
unrel
serum
ige
level
skin
prick
test
posit
contrast
allerg
rhiniti
product
heterogen
bachert
et
al
demonstr
three
differ
categori
patient
nasal
polyposi
group
demonstr
measur
specif
ige
nasal
polyposi
group
select
specif
ige
third
group
demonstr
multiclon
specif
ige
includ
ige
aureu
enterotoxin
high
total
ige
level
high
preval
asthma
latter
group
patient
usual
sensit
aspirin
consid
treatment
interest
note
chines
patient
neutrophil
eosinophil
polyp
polyp
also
seen
inherit
diseas
primari
ciliari
diskinesia
cystic
fibrosi
chines
patient
polyp
character
b
tcell
activ
minor
eosinophil
inflamm
compar
polyp
white
individu
decreas
comparison
control
one
third
patient
polyp
show
ige
respons
aureu
enterotoxin
figur
show
put
mechan
cell
mediat
impli
cr
polyp
chines
polyp
manag
nasal
polyp
extrem
individu
must
discuss
case
case
expect
one
patient
necessari
other
treatment
medic
surgic
goal
treatment
reestablish
nasal
airway
nasal
breath
minim
symptom
improv
sens
smell
treat
coexist
diseas
asthma
improv
qualiti
life
prevent
complic
start
therapi
import
inform
patient
nasal
polyposi
chronic
sinu
diseas
imposs
cure
potenti
stabil
differ
medic
recurr
rule
observ
complianc
treatment
postpon
long
possibl
relaps
diseas
samter
triad
import
avoid
definit
form
acetylsalicyl
acid
nsaid
corticosteroid
firstchoic
treatment
approach
eosinophil
polyposi
suppress
mani
phase
inflammatori
process
exampl
inhibit
liber
vasoact
mediat
reduc
vasodilat
fluid
extravas
edema
local
deposit
mediat
also
reduc
recruit
inflammatori
cell
fibroblast
prolifer
synthesi
extracellular
matrix
protein
system
applic
affect
polyp
tissu
within
nose
sinus
disadvantag
system
advers
effect
use
longterm
treatment
hissaria
et
al
demonstr
random
placebocontrol
trial
efficaci
cours
mg
prednisolon
patient
symptom
qualiti
life
endoscop
score
nevertheless
clinic
point
view
patient
may
experi
rebound
effect
cours
system
corticosteroid
topic
applic
corticosteroid
dramat
reduc
risk
system
side
effect
mani
studi
demonstr
safeti
efficaci
in
nasal
polyposi
even
intrasinu
portion
polyp
reachabl
nasal
spray
among
special
mometason
furoat
fluticason
furoat
newest
safest
molecul
lowest
bioavail
nasal
polyposi
antibiot
full
dose
recommend
treat
acut
bacteri
exacerb
sinus
recent
year
consider
evid
emerg
suggest
macrolid
antibiot
low
dose
could
play
role
treatment
nasal
polyposi
macrolid
immunomodulatori
properti
addit
wellestablish
antimicrobi
activ
inde
macrolid
antibiot
inhibit
synthesi
andor
secret
proinflammatori
cytkin
granulocytemacrophag
colonystimul
factor
tumor
necrosi
factor
mani
effect
neutrophil
decreas
neutrophil
oxid
burst
inhibit
neutrophil
migrat
inflammatori
site
increas
apoptosi
neutrophil
inhibit
neutrophil
adhes
also
decreas
eosinophil
inflamm
reduc
goblet
cell
secret
decreas
bronchoconstrict
studi
confirm
clinic
efficaci
signific
reduct
size
polyp
reduct
symptom
nasal
obstruct
nasal
discharg
purul
headach
relaps
polyp
seem
delay
howev
studi
demonstr
necess
longterm
use
month
slow
onset
week
treatment
patient
indic
improv
week
improv
week
improv
week
improv
consid
longterm
treatment
gastrointestin
intoler
problem
observ
treatment
moreov
low
dose
emerg
antibioticresist
bacteria
taken
consider
antihistamin
typic
one
medic
choic
treat
allerg
rhiniti
despit
sever
theoret
pharmacolog
properti
applic
treatment
nasal
polyposi
consensu
group
newgener
antihistmain
conga
littl
publish
indic
antileukotrien
shown
effect
nasal
polyposi
chang
arachidon
acid
metabol
suggest
involv
pathogenesi
nasal
polyposi
especi
aspirinsensit
individu
cysteinyl
leukotrien
found
increas
level
nasal
tissu
patient
wherea
concentr
prostaglandin
decreas
furthermor
leukotrien
synthas
found
upregul
patient
nasal
polyp
number
leukocyt
express
cysteinyl
leukotrien
receptor
compar
counterpart
thu
use
leukotrien
antagonist
especi
aspirinsensit
nasal
polyp
patient
seem
appropri
howev
largescal
control
trial
clearli
character
without
aspirin
lack
thu
far
patient
aspirin
sensit
aspirin
desensit
recommend
aspirin
desensit
consist
administ
increment
oral
dose
reach
mainten
dose
greater
mgd
induc
refractori
period
day
continu
treatment
year
may
lead
signific
reduct
number
sinu
infect
per
year
improv
olfact
reduct
use
system
corticosteroid
treatment
daili
aspirin
may
therapeut
option
patient
respond
topic
system
corticosteroid
new
treatment
option
must
consid
doxycyclin
antiig
doxycyclin
antibiot
also
inhibit
synthesi
mmp
activ
vitro
howev
doxycyclin
affect
inhibitor
tissu
inhibitor
metalloproteinas
doubleblind
placebocontrol
studi
demonstr
patient
signific
decreas
endoscop
nasal
polyp
score
week
start
doxyclin
treatment
compar
placebo
concentr
ige
myeloperoxidas
ecp
decreas
significantli
nasal
secret
doxycyclinetr
patient
clinic
set
use
doxycyclin
offer
addit
advantag
provid
antimicrobi
antiinflammatori
effect
result
decreas
nasal
polyp
size
increas
polyp
tissu
relat
eosinophil
inflamm
monoclon
antibodi
treatment
vitro
induc
eosinophil
apoptosi
cytokin
reason
target
antibodi
therapi
nasal
polyp
differ
human
monoclon
antibodi
develop
studi
asthma
pilot
studi
nasal
polyposi
provid
promis
result
consid
mark
local
product
ige
antibodi
nasal
polyp
relat
sever
diseas
appear
local
ige
function
involv
regul
chronic
inflamm
thu
strategi
antagon
ige
could
relev
treatment
allerg
asthma
rhiniti
omalizumab
human
antiig
monoclon
antibodi
caus
mark
reduct
circul
free
ige
level
studi
nasal
polyposi
publish
howev
least
two
team
alreadi
thought
possibl
clinic
applic
antiig
sever
nasal
polyposi
regardless
whether
associ
corticodepend
asthma
manag
nasal
polyposi
usual
involv
medic
treatment
frequent
surgeri
adjunct
medic
treatment
surgic
remov
nasal
polyp
indic
patient
respond
adequ
medic
manag
continu
recurr
infect
well
patient
develop
mucocel
complic
sinus
patient
polyp
asthma
may
benefit
surgeri
reduct
one
trigger
asthma
type
surgeri
perform
subject
debat
europ
respect
place
endoscopicguid
polypectomi
versu
function
endoscop
sinu
surgeri
versu
nasal
recommend
dr
jankowski
nanci
function
endoscop
sinu
surgeri
still
gold
standard
must
open
ethmoid
compart
must
clear
frontal
recess
complet
must
larg
sphenoidotomi
case
question
remain
unansw
long
complet
ethmoidectomi
recommend
power
instrument
microdebrid
appear
particularli
help
extens
polyposi
allow
precis
remov
polyp
good
visual
control
preserv
anatomi
minim
mucos
trauma
strip
guarante
minim
crust
format
rapid
mucos
heal
low
incid
synechia
format
revis
surgeri
anatomi
highli
distort
even
huge
polyposi
surgeri
conduct
navig
system
give
surgeon
confid
particularli
frontal
sinu
area
sphenoid
sinu
seem
reduc
rate
complic
endoscop
sinu
surgeri
shown
lead
signific
improv
total
nasal
resist
measur
rhinomanometri
nasal
volum
measur
acoust
rhinometri
ciliari
beat
frequenc
mucociliari
clearanc
measur
saccharin
test
olfact
measur
univers
pennsylvania
smell
identif
test
increas
evid
also
indic
manag
polyposi
benefit
lower
airway
patient
healthrel
qualiti
life
howev
surgeri
complet
final
definit
step
treat
nasal
polyposi
remain
long
know
chronic
inflammatori
diseas
whose
etiolog
pathophysiolog
still
poorli
understood
longterm
treatment
topic
steroid
surgeri
remain
rule
eosinophil
polyp
reduc
incid
polyp
recurr
prolong
symptomfre
time
interv
rhinosinus
repres
larg
heterogen
group
diseas
ar
mainli
inflammatori
disord
initi
viral
infect
in
seem
best
first
option
treatment
mild
moder
case
cr
without
polyp
mainli
neutrophil
inflamm
antibiot
combin
in
first
choic
treatment
function
sinu
surgeri
usual
necessari
improv
patient
cr
polyp
frustrat
diseas
clinician
recurr
rule
asthma
aspirin
intoler
common
comorbid
caucasian
patient
associ
eosinophil
infiltr
fungi
aureu
enterotoxin
could
play
role
pathophysiolog
glucocorticoid
associ
larg
sinu
surgeri
long
time
treatment
new
treatment
option
seem
promis
specif
doxycyclin
antiig
